Dosage and Administration Prevention of Chemotherapy Induced Nausea and Vomiting (cinv)
ثبت نشده
چکیده
PRESENTATIONS 40 mg: A size #4 opaque, hard gelatin capsule with white body and mustard yellow cap with “464” and “40 mg” printed radially in black ink. Dimensions are overall length 14.3 mm. Not currently available in New Zealand. 80 mg: A size #2 opaque, hard gelatin capsule with white body and white cap with “461” and “80 mg” printed radially in black ink. Dimensions are overall length 18.0 mm.
منابع مشابه
The Role of Clinical Guidelines for the Management of Chemotherapy-Induced Nausea and Vomiting in Children with Cancer
Background: Nausea and vomiting are among the most important side-effects associated with chemotherapy in children with cancer, affecting the quality of their lives. Clinical guidelines for selecting antiemetics are effective in reducing acute chemotherapy-induced nausea and vomiting (CINV). Materials and Methods: The present quasi-experimental study compared the effectiveness of the Pediatric...
متن کاملProfile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV. The use of a combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has ...
متن کاملPrevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
Prevention of nausea and vomiting is the main goal of antiemetic treatment in cancer patients scheduled to receive chemotherapy. To prevent acute emesis, antiemetics should be administered just before chemotherapy and patients should be protected for up to 24 hours after chemotherapy initiation. The emetogenic potential of chemotherapeutic agents guides clinicians towards the most appropriate a...
متن کاملA Prospective Triple-blind Randomized Trial on Safety and Efficacy of Abitant in the Prevention of Chemotherapy-Induced Nausea and Vomiting
Background: Oral Aprepitant, a neurokinin-1 receptor antagonist, is suggested in combination with other antiemetic agents in preventing chemotherapy-induced nausea and vomiting(CINV) associated with emetogenic chemotherapeutic regimens in adolescents, but its efficacy and safety in pediatric patients more than six months are unknown. in this study, we used abitant drug (a generic name of Aprepi...
متن کاملThe nurse's role in managing chemotherapy-induced nausea and vomiting: an international survey.
BACKGROUND Nurses play a substantial role in the prevention and management of chemotherapy-induced nausea and vomiting (CINV). OBJECTIVES This study set out to describe nurses' roles in the prevention and management of CINV and to identify any gaps that exist across countries. METHODS A self-reported survey was completed by 458 registered nurses who administered chemotherapy to cancer patie...
متن کاملNew options and controversies in the management of chemotherapy-induced nausea and vomiting.
PURPOSE An expanding array of options for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), including regimens containing olanzapine or recently approved neurokinin 1 (NK1) receptor antagonists, are reviewed. SUMMARY Up to 80% of patients receiving chemotherapy have CINV. Current practice guidelines recommend that patients treated with highly emetogenic chemotherapy...
متن کامل